CG Oncology (CGON) Revenue (2023 - 2026)

CG Oncology (CGON) reported Revenue of $1.1 million for Q1 2026, up 1982.69% on a YoY basis from $52000.0 in Q1 2025, and down 53.36% quarter-over-quarter from $2.3 million in Q4 2025.

CG Oncology (CGON) Revenue (2023 - 2026) Analysis & Trends

CG Oncology has reported Revenue for 4 years, with the latest figure at $1.1 million in Q1 2026.

  • For the quarter ending Q1 2026, Revenue rose 1982.69% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $5.1 million (up 666.01% YoY), and the FY2025 full-year result was $4.0 million, up 254.7% from the prior year.
  • Revenue for Q1 2026 stood at $1.1 million, down from $2.3 million in the prior quarter.
  • The five-year high for Revenue was $2.3 million in Q4 2025, with the low at $1000.0 in Q4 2023.
  • Historically, Revenue has averaged $587818.2 across 4 years, with a median of $194000.0 in 2023.
  • Annual changes were most pronounced in 2024 — Revenue jumped 45500.0% — and 2025, when it slumped 90.17%.
  • CG Oncology's Revenue stood at $1000.0 in 2023, then jumped by 45500.0% to $456000.0 in 2024, then jumped by 409.21% to $2.3 million in 2025, then sank by 53.36% to $1.1 million in 2026.
  • The last three Revenue figures came in at $1.1 million (Q1 2026), $2.3 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 5.21 Mn
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 306.30 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 2.99 Bn
9 Abivax 91.96 Bn 91.96 Bn - -
10 CG Oncology 5.16 Bn 5.16 Bn -1.88 Mn 1.08 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.08 Mn
Dec 31, 2025 2.32 Mn
Sep 30, 2025 1.67 Mn
Mar 31, 2025 52,000.00
Dec 31, 2024 456,000.00
Sep 30, 2024 43,000.00
Jun 30, 2024 111,000.00
Mar 31, 2024 529,000.00
Dec 31, 2023 1,000.00
Sep 30, 2023 9,000.00
Mar 31, 2023 194,000.00